Tetracosactide - Novartis
Alternative Names: Corticotropin tetracosapeptide; Cosyntropin; MNK-1411; Synacthen; Synacthen Depot; Tetracosactide hexa-acetate salt - NovartisLatest Information Update: 28 Sep 2022
At a glance
- Originator Novartis
- Developer Alliance Pharmaceuticals Limited; Defiante Farmaceutica; Leadiant Biosciences; Mallinckrodt plc; Novartis; Swedish Orphan Biovitrum
- Class Anti-inflammatories; Antidepressants; Corticosteroids; Diagnostic agents; Immunotherapies; Melanocortins; Peptides
- Mechanism of Action Melanocortin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Adrenal insufficiency; Autoimmune disorders; Infantile spasms; Inflammation; Multiple sclerosis
- Discontinued Duchenne muscular dystrophy
Most Recent Events
- 28 Sep 2022 Discontinued - Phase-II for Duchenne muscular dystrophy (In children) in Belgium (SC)
- 28 Sep 2022 Discontinued - Phase-II for Duchenne muscular dystrophy (In children) in Bulgaria (SC)
- 28 Sep 2022 Discontinued - Phase-II for Duchenne muscular dystrophy (In children) in Israel (SC)